Sastasundar Ventures Limited has informed the Exchange regarding Disclosure under Regulation 30 of SEBI (LODR) - Outcome of Board Meeting held on February 27, 2026.
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Health X Platform's board on February 27, 2026 approved a Tripartite Agreement between the company, its material subsidiary Sastasundar Healthbuddy Limited (SHBL), and Envision India Fund (a Mauritius-based qualified institutional buyer). This follows a Share Purchase Agreement dated February 25, 2026, where Envision agreed to acquire the entire shareholding of Japan's Mitsubishi Corporation in SHBL. The agreement contemplates merging SHBL into HealthX in a way that preserves Envision's economic interest, with a share swap arrangement as a fallback if the merger cannot be completed. Envision also gets the right to nominate one director on HealthX's board in case of merger non-consummation or material breach. Post-transaction shareholding of SHBL will be: HealthX with 17,100,160 shares (~78.9%), Rohto Pharmaceuticals with 3,562,064 shares (~16.4%), and Envision with 1,013,766 shares (~4.7%), totalling 21,675,990 shares.
For shareholders, this signals an ongoing corporate restructuring where the listed entity will absorb its material subsidiary, potentially simplifying the group structure. Investors should watch for the next steps including the formal filing of the scheme of arrangement with NCLT and the announcement of the actual share swap ratio. The entry of Envision as a new institutional investor with board nomination rights may also bring governance changes.